Australia's ChemGenex said it soon will begin a Phase II trial on its cancer drug, ceflatonin, for treating advanced cancer patients resistant to Gleevec, the only treatment available for chronic myelogenous leukemia. The drug completed Phase II trials about five years ago, but Novartis' Gleevec beat it to market before the resistance was discovered.

Related Summaries